The Roadmap of RANKL/RANK Pathway in Cancer

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

(2021) Sandra Benítez et al.   DEVELOPMENTAL CELL

A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression

(2021) Julia N. Cheng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences

(2021) Stella D'Oronzo et al.   Journal of Bone Oncology

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer

(2020) Francesco Pantano et al.   Scientific Reports

Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer

(2020) Inês Gomes et al.   Oncotarget

Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis

(2020) Dirk Geerts et al.   Frontiers in Oncology

BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES

(2020) R. Coleman et al.   ANNALS OF ONCOLOGY

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

(2020) Solange Peters et al.   Journal of Thoracic Oncology

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

Bone metastases

(2020) Robert E. Coleman et al.   Nature Reviews Disease Primers

Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions

(2020) Christopher N. George et al.   Journal of Bone Oncology

The RANK–RANKL axis: an opportunity for drug repurposing in cancer?

(2019) S. Peters et al.   Clinical & Translational Oncology

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Michael Gnant et al.   LANCET ONCOLOGY

Current Landscape of Immunotherapy in Breast Cancer

(2019) Sylvia Adams et al.   JAMA Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases

(2019) Yenny Angela et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

(2019) Roger von Moos et al.   CANCER TREATMENT REVIEWS

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

(2019) Robert Coleman et al.   LANCET ONCOLOGY

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

(2018) A.F. de Groot et al.   CANCER TREATMENT REVIEWS

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma

(2018) Muhammad Z. Afzal et al.   MELANOMA RESEARCH

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer

(2018) Alexander Liede et al.   OncoImmunology

RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment

(2018) Peter A. van Dam et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline

(2017) Sukhbinder Dhesy-Thind et al.   JOURNAL OF CLINICAL ONCOLOGY

Review of cancer treatment with immune checkpoint inhibitors

(2017) Christiane Thallinger et al.   WIENER KLINISCHE WOCHENSCHRIFT

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells

(2017) Elisabet Cuyàs et al.   Oncotarget

RANK-RANKL signalling in cancer

(2016) N. Renema et al.   BIOSCIENCE REPORTS

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

(2016) Joanne Kotsopoulos et al.   BREAST CANCER RESEARCH AND TREATMENT

RANKL/RANK control Brca1 mutation-driven mammary tumors

(2016) Verena Sigl et al.   CELL RESEARCH

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma

(2016) Mark J. Smyth et al.   JOURNAL OF CLINICAL ONCOLOGY

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment

(2016) Jules A. Westbrook et al.   JNCI-Journal of the National Cancer Institute

STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply

(2016) Nicholas D James et al.   LANCET

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

(2016) Emma Nolan et al.   NATURE MEDICINE

RANKL Signaling and ErbB Receptors in Breast Carcinogenesis

(2016) Ilianna Zoi et al.   TRENDS IN MOLECULAR MEDICINE

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

(2016) N Raje et al.   Blood Cancer Journal

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment

(2016) Jules A. Westbrook et al.   JNCI-Journal of the National Cancer Institute

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

(2015) Manfred Wirth et al.   EUROPEAN UROLOGY

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

(2015) Milica Pavlovic et al.   JNCI-Journal of the National Cancer Institute

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

(2015)   LANCET

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

(2015) Milica Pavlovic et al.   JNCI-Journal of the National Cancer Institute

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

(2015) Martin Widschwendter et al.   EBioMedicine

How Do Bisphosphonates Inhibit Bone Metastasis In Vivo

(2015) Pierrick G. Fournier et al.   NEOPLASIA

RANK expression as a prognostic and predictive marker in breast cancer

(2014) Berit Maria Pfitzner et al.   BREAST CANCER RESEARCH AND TREATMENT

Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo

(2014) P. D. Ottewell et al.   CLINICAL CANCER RESEARCH

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer

(2014) Hyung Seok Park et al.   JOURNAL OF SURGICAL ONCOLOGY

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

(2014) Robert Coleman et al.   LANCET ONCOLOGY

Endocrine aspects of bone metastases

(2014) Lorenz C Hofbauer et al.   Lancet Diabetes & Endocrinology

RANK expression on breast cancer cells promotes skeletal metastasis

(2013) Michelle L. Blake et al.   CLINICAL & EXPERIMENTAL METASTASIS

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

(2013) G. J. Morgan et al.   CLINICAL CANCER RESEARCH

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines

(2013) Masanobu Tsubaki et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro

(2013) Sandra Casimiro et al.   PLoS One

Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast

(2013) T. Tanos et al.   Science Translational Medicine

Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis

(2013) Pasquale Pellegrini et al.   STEM CELLS

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

(2013) David Henry et al.   SUPPORTIVE CARE IN CANCER

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

(2012) Jude Canon et al.   BREAST CANCER RESEARCH AND TREATMENT

RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis

(2012) M. Palafox et al.   CANCER RESEARCH

In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger V 9V 2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement

(2012) I. Benzaid et al.   CLINICAL CANCER RESEARCH

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

(2012) Allan Lipton et al.   EUROPEAN JOURNAL OF CANCER

Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation

(2012) Tomohiro Itoh et al.   JOURNAL OF MOLECULAR HISTOLOGY

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

(2012) Giorgio Vittorio Scagliotti et al.   Journal of Thoracic Oncology

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

(2012) David L. Lacey et al.   NATURE REVIEWS DRUG DISCOVERY

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo

(2011) I. Benzaid et al.   CANCER RESEARCH

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis

(2011) Lingyun Zhang et al.   JOURNAL OF CLINICAL PATHOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling

(2011) Wei Tan et al.   NATURE

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

(2011) Daniele Santini et al.   PLoS One

Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis

(2010) Allan Lipton et al.   BONE

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases

(2010) Daniele Santini et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

(2010) Eva Gonzalez-Suarez et al.   NATURE

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

(2010) S. Ferrari-Lacraz et al.   OSTEOPOROSIS INTERNATIONAL

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland

(2010) M. Beleut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis

(2009) X. Lu et al.   GENES & DEVELOPMENT

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway

(2009) Marta Coscia et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas

(2009) Shuji Mikami et al.   JOURNAL OF PATHOLOGY

Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα

(2009) E C Merkhofer et al.   ONCOGENE